| Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription A Siddiqui-Jain, CL Grand, DJ Bearss, LH Hurley Proceedings of the National Academy of Sciences 99 (18), 11593-11598, 2002 | 2515 | 2002 |
| An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor … LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ... Clinical cancer research 19 (1), 279-290, 2013 | 1003 | 2013 |
| Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3 WM Yang, C Inouye, Y Zeng, D Bearss, E Seto Proceedings of the National Academy of Sciences 93 (23), 12845-12850, 1996 | 730 | 1996 |
| The Cationic Porphyrin TMPyP4 Down-Regulates c-MYC and Human Telomerase Reverse Transcriptase Expression and Inhibits Tumor Growth in Vivo CL Grand, H Han, RM Munoz, S Weitman, DD Von Hoff, LH Hurley, ... Molecular cancer therapeutics 1 (8), 565-573, 2002 | 522 | 2002 |
| Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray H Han, DJ Bearss, LW Browne, R Calaluce, RB Nagle, DD Von Hoff Cancer research 62 (10), 2890-2896, 2002 | 471 | 2002 |
| A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors D Mahadevan, L Cooke, C Riley, R Swart, B Simons, K Della Croce, ... Oncogene 26 (27), 3909-3919, 2007 | 347 | 2007 |
| NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers W Zhou, Y Yang, J Xia, H Wang, ME Salama, W Xiong, H Xu, S Shetty, ... Cancer cell 23 (1), 48-62, 2013 | 306 | 2013 |
| Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells W Fiskus, S Sharma, B Shah, BP Portier, SGT Devaraj, K Liu, SP Iyer, ... Leukemia 28 (11), 2155-2164, 2014 | 292 | 2014 |
| Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo: implications for human breast cancer JA Engelman, RJ Lee, A Karnezis, DJ Bearss, M Webster, P Siegel, ... Journal of Biological Chemistry 273 (32), 20448-20455, 1998 | 282 | 1998 |
| Targeting Axl and Mer kinases in cancer A Verma, SL Warner, H Vankayalapati, DJ Bearss, S Sharma Molecular cancer therapeutics 10 (10), 1763-1773, 2011 | 262 | 2011 |
| Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells LS Chen, S Redkar, D Bearss, WG Wierda, V Gandhi Blood, The Journal of the American Society of Hematology 114 (19), 4150-4157, 2009 | 236 | 2009 |
| Targeting Aurora-2 kinase in cancer SL Warner, DJ Bearss, H Han, DD Von Hoff Molecular cancer therapeutics 2 (6), 589-595, 2003 | 233 | 2003 |
| A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis RE Barrington, MA Subler, E Rands, CA Omer, PJ Miller, JE Hundley, ... Molecular and cellular biology 18 (1), 85-92, 1998 | 218 | 1998 |
| Telomeres and telomerases as drug targets EM Rezler, DJ Bearss, LH Hurley Current opinion in pharmacology 2 (4), 415-423, 2002 | 205 | 2002 |
| High-Throughput Virtual Screening Identifies Novel N′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors V Sorna, ER Theisen, B Stephens, SL Warner, DJ Bearss, ... Journal of medicinal chemistry 56 (23), 9496-9508, 2013 | 203 | 2013 |
| Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma S Sankar, R Bell, B Stephens, R Zhuo, S Sharma, DJ Bearss, SL Lessnick Oncogene 32 (42), 5089-5100, 2013 | 176 | 2013 |
| S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth JC Chuang, SL Warner, D Vollmer, H Vankayalapati, S Redkar, ... Molecular cancer therapeutics 9 (5), 1443-1450, 2010 | 176 | 2010 |
| Telomere inhibition and telomere disruption as processes for drug targeting EM Rezler, DJ Bearss, LH Hurley Annual Review of Pharmacology and Toxicology 43 (1), 359-379, 2003 | 173 | 2003 |
| Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia IK Park, B Mundy-Bosse, SP Whitman, X Zhang, SL Warner, DJ Bearss, ... Leukemia 29 (12), 2382-2389, 2015 | 158 | 2015 |
| Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes SM Mumenthaler, PYB Ng, A Hodge, D Bearss, G Berk, S Kanekal, ... Molecular cancer therapeutics 8 (10), 2882-2893, 2009 | 156 | 2009 |
Steven WarnerTolero PharmaceuticalsVerified email at toleropharma.com
